Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Multiple-dose, Crossover Phase I Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32 mg and Dilatrend Tablet 25 mg in Healthy Male Subjects
Conditions
Interventions
Dilatrend SR capsule 32mg
Dilatrend IR tablet 25mg
Locations
1
South Korea
Kyungpook National University Hospital Clinical Trial Center
Daegu, Eok-dong 2(i)-ga Jung-gu, South Korea
Start Date
April 1, 2013
Primary Completion Date
May 1, 2013
Completion Date
August 1, 2013
Last Updated
April 1, 2013
NCT06823947
NCT05507879
NCT04551560
NCT07101289
NCT03994874
NCT04100148
Lead Sponsor
Chong Kun Dang Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions